nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—Protein Kinase Inhibitors—Ruxolitinib—hematologic cancer	0.253	0.5	CiPCiCtD
Everolimus—Protein Kinase Inhibitors—Nilotinib—hematologic cancer	0.253	0.5	CiPCiCtD
Everolimus—MTOR—hematologic cancer	0.202	1	CbGaD
Everolimus—CYP3A4—Bexarotene—hematologic cancer	0.00883	0.0829	CbGbCtD
Everolimus—CYP3A4—Busulfan—hematologic cancer	0.00821	0.0771	CbGbCtD
Everolimus—CYP3A4—Lomustine—hematologic cancer	0.00821	0.0771	CbGbCtD
Everolimus—CYP3A4—Thiotepa—hematologic cancer	0.00731	0.0687	CbGbCtD
Everolimus—CYP3A4—Methoxsalen—hematologic cancer	0.00569	0.0534	CbGbCtD
Everolimus—CYP3A4—Bortezomib—hematologic cancer	0.00541	0.0508	CbGbCtD
Everolimus—CYP3A4—Daunorubicin—hematologic cancer	0.00517	0.0486	CbGbCtD
Everolimus—CYP3A4—Cytarabine—hematologic cancer	0.00456	0.0429	CbGbCtD
Everolimus—CYP3A4—Teniposide—hematologic cancer	0.0045	0.0422	CbGbCtD
Everolimus—CYP3A4—Ifosfamide—hematologic cancer	0.00415	0.039	CbGbCtD
Everolimus—CYP3A4—Imatinib—hematologic cancer	0.00396	0.0372	CbGbCtD
Everolimus—CYP3A4—Ruxolitinib—hematologic cancer	0.00373	0.0351	CbGbCtD
Everolimus—CYP3A4—Nilotinib—hematologic cancer	0.0036	0.0338	CbGbCtD
Everolimus—CYP3A4—Vinorelbine—hematologic cancer	0.00357	0.0335	CbGbCtD
Everolimus—CYP3A4—Triamcinolone—hematologic cancer	0.00327	0.0307	CbGbCtD
Everolimus—CYP3A4—Dasatinib—hematologic cancer	0.00318	0.0299	CbGbCtD
Everolimus—CYP3A4—Mitoxantrone—hematologic cancer	0.00314	0.0295	CbGbCtD
Everolimus—CYP3A4—Betamethasone—hematologic cancer	0.0028	0.0263	CbGbCtD
Everolimus—CYP3A4—Prednisolone—hematologic cancer	0.00277	0.026	CbGbCtD
Everolimus—CYP3A4—Prednisone—hematologic cancer	0.00261	0.0245	CbGbCtD
Everolimus—CYP3A4—Irinotecan—hematologic cancer	0.00248	0.0232	CbGbCtD
Everolimus—CYP3A4—Vinblastine—hematologic cancer	0.0022	0.0207	CbGbCtD
Everolimus—CYP3A4—Vincristine—hematologic cancer	0.00216	0.0203	CbGbCtD
Everolimus—CYP3A4—Etoposide—hematologic cancer	0.00198	0.0186	CbGbCtD
Everolimus—CYP3A4—Dexamethasone—hematologic cancer	0.00163	0.0153	CbGbCtD
Everolimus—CYP3A4—Doxorubicin—hematologic cancer	0.00135	0.0127	CbGbCtD
Everolimus—MTOR—hematopoietic system—hematologic cancer	0.00114	0.109	CbGeAlD
Everolimus—FKBP1A—hematopoietic system—hematologic cancer	0.00103	0.0977	CbGeAlD
Everolimus—MTOR—gonad—hematologic cancer	0.000869	0.0826	CbGeAlD
Everolimus—FKBP1A—gonad—hematologic cancer	0.000782	0.0743	CbGeAlD
Everolimus—MTOR—blood—hematologic cancer	0.000757	0.0719	CbGeAlD
Everolimus—MTOR—bone marrow—hematologic cancer	0.000733	0.0696	CbGeAlD
Everolimus—FKBP1A—blood—hematologic cancer	0.000681	0.0647	CbGeAlD
Everolimus—MTOR—lung—hematologic cancer	0.000664	0.0631	CbGeAlD
Everolimus—FKBP1A—bone marrow—hematologic cancer	0.000659	0.0626	CbGeAlD
Everolimus—MTOR—testis—hematologic cancer	0.000627	0.0595	CbGeAlD
Everolimus—FKBP1A—lung—hematologic cancer	0.000597	0.0567	CbGeAlD
Everolimus—FKBP1A—testis—hematologic cancer	0.000564	0.0535	CbGeAlD
Everolimus—Pimecrolimus—MTOR—hematologic cancer	0.000511	0.249	CrCbGaD
Everolimus—MTOR—lymph node—hematologic cancer	0.000454	0.0431	CbGeAlD
Everolimus—FKBP1A—lymph node—hematologic cancer	0.000408	0.0388	CbGeAlD
Everolimus—Sirolimus—FGF2—hematologic cancer	0.000373	0.181	CrCbGaD
Everolimus—Temsirolimus—MTOR—hematologic cancer	0.000345	0.168	CrCbGaD
Everolimus—CYP3A4—hematopoietic system—hematologic cancer	0.000336	0.0319	CbGeAlD
Everolimus—Sirolimus—MTOR—hematologic cancer	0.000304	0.148	CrCbGaD
Everolimus—Tacrolimus—MTOR—hematologic cancer	0.000304	0.148	CrCbGaD
Everolimus—CYP3A4—blood—hematologic cancer	0.000223	0.0211	CbGeAlD
Everolimus—Temsirolimus—ABCB1—hematologic cancer	5.93e-05	0.0289	CrCbGaD
Everolimus—Tacrolimus—ALB—hematologic cancer	5.47e-05	0.0266	CrCbGaD
Everolimus—Tacrolimus—ABCB1—hematologic cancer	5.22e-05	0.0254	CrCbGaD
Everolimus—Sirolimus—ABCB1—hematologic cancer	5.22e-05	0.0254	CrCbGaD
Everolimus—Alopecia—Epirubicin—hematologic cancer	4.42e-06	3.99e-05	CcSEcCtD
Everolimus—Skin disorder—Prednisone—hematologic cancer	4.41e-06	3.98e-05	CcSEcCtD
Everolimus—Nausea—Gemcitabine—hematologic cancer	4.41e-06	3.98e-05	CcSEcCtD
Everolimus—Vomiting—Cisplatin—hematologic cancer	4.4e-06	3.97e-05	CcSEcCtD
Everolimus—Hyperhidrosis—Prednisone—hematologic cancer	4.39e-06	3.97e-05	CcSEcCtD
Everolimus—Vision blurred—Methotrexate—hematologic cancer	4.38e-06	3.96e-05	CcSEcCtD
Everolimus—Mental disorder—Epirubicin—hematologic cancer	4.38e-06	3.96e-05	CcSEcCtD
Everolimus—Rash—Cisplatin—hematologic cancer	4.36e-06	3.94e-05	CcSEcCtD
Everolimus—Dermatitis—Cisplatin—hematologic cancer	4.36e-06	3.94e-05	CcSEcCtD
Everolimus—Erythema—Epirubicin—hematologic cancer	4.35e-06	3.93e-05	CcSEcCtD
Everolimus—Malnutrition—Epirubicin—hematologic cancer	4.35e-06	3.93e-05	CcSEcCtD
Everolimus—Diarrhoea—Etoposide—hematologic cancer	4.34e-06	3.92e-05	CcSEcCtD
Everolimus—Anorexia—Prednisone—hematologic cancer	4.33e-06	3.91e-05	CcSEcCtD
Everolimus—Eye disorder—Doxorubicin—hematologic cancer	4.32e-06	3.9e-05	CcSEcCtD
Everolimus—Ill-defined disorder—Methotrexate—hematologic cancer	4.31e-06	3.9e-05	CcSEcCtD
Everolimus—Anaemia—Methotrexate—hematologic cancer	4.3e-06	3.88e-05	CcSEcCtD
Everolimus—Feeling abnormal—Dexamethasone—hematologic cancer	4.3e-06	3.88e-05	CcSEcCtD
Everolimus—Feeling abnormal—Betamethasone—hematologic cancer	4.3e-06	3.88e-05	CcSEcCtD
Everolimus—Flushing—Doxorubicin—hematologic cancer	4.29e-06	3.88e-05	CcSEcCtD
Everolimus—Cardiac disorder—Doxorubicin—hematologic cancer	4.29e-06	3.88e-05	CcSEcCtD
Everolimus—Flatulence—Epirubicin—hematologic cancer	4.29e-06	3.87e-05	CcSEcCtD
Everolimus—Gastrointestinal pain—Dexamethasone—hematologic cancer	4.26e-06	3.85e-05	CcSEcCtD
Everolimus—Gastrointestinal pain—Betamethasone—hematologic cancer	4.26e-06	3.85e-05	CcSEcCtD
Everolimus—Dysgeusia—Epirubicin—hematologic cancer	4.26e-06	3.85e-05	CcSEcCtD
Everolimus—Hypersensitivity—Triamcinolone—hematologic cancer	4.23e-06	3.82e-05	CcSEcCtD
Everolimus—Back pain—Epirubicin—hematologic cancer	4.21e-06	3.8e-05	CcSEcCtD
Everolimus—Angiopathy—Doxorubicin—hematologic cancer	4.2e-06	3.79e-05	CcSEcCtD
Everolimus—Malaise—Methotrexate—hematologic cancer	4.19e-06	3.79e-05	CcSEcCtD
Everolimus—Dizziness—Etoposide—hematologic cancer	4.19e-06	3.78e-05	CcSEcCtD
Everolimus—Muscle spasms—Epirubicin—hematologic cancer	4.18e-06	3.78e-05	CcSEcCtD
Everolimus—Immune system disorder—Doxorubicin—hematologic cancer	4.18e-06	3.77e-05	CcSEcCtD
Everolimus—Mediastinal disorder—Doxorubicin—hematologic cancer	4.17e-06	3.77e-05	CcSEcCtD
Everolimus—Leukopenia—Methotrexate—hematologic cancer	4.16e-06	3.76e-05	CcSEcCtD
Everolimus—Chills—Doxorubicin—hematologic cancer	4.15e-06	3.75e-05	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Prednisone—hematologic cancer	4.14e-06	3.74e-05	CcSEcCtD
Everolimus—Dizziness—Prednisolone—hematologic cancer	4.13e-06	3.73e-05	CcSEcCtD
Everolimus—Asthenia—Triamcinolone—hematologic cancer	4.12e-06	3.72e-05	CcSEcCtD
Everolimus—Abdominal pain—Dexamethasone—hematologic cancer	4.12e-06	3.72e-05	CcSEcCtD
Everolimus—Abdominal pain—Betamethasone—hematologic cancer	4.12e-06	3.72e-05	CcSEcCtD
Everolimus—Body temperature increased—Dexamethasone—hematologic cancer	4.12e-06	3.72e-05	CcSEcCtD
Everolimus—Body temperature increased—Betamethasone—hematologic cancer	4.12e-06	3.72e-05	CcSEcCtD
Everolimus—Nausea—Cisplatin—hematologic cancer	4.11e-06	3.71e-05	CcSEcCtD
Everolimus—Insomnia—Prednisone—hematologic cancer	4.11e-06	3.71e-05	CcSEcCtD
Everolimus—Vision blurred—Epirubicin—hematologic cancer	4.1e-06	3.7e-05	CcSEcCtD
Everolimus—Alopecia—Doxorubicin—hematologic cancer	4.09e-06	3.69e-05	CcSEcCtD
Everolimus—Paraesthesia—Prednisone—hematologic cancer	4.08e-06	3.68e-05	CcSEcCtD
Everolimus—Pruritus—Triamcinolone—hematologic cancer	4.07e-06	3.67e-05	CcSEcCtD
Everolimus—Cough—Methotrexate—hematologic cancer	4.06e-06	3.67e-05	CcSEcCtD
Everolimus—Mental disorder—Doxorubicin—hematologic cancer	4.05e-06	3.66e-05	CcSEcCtD
Everolimus—Ill-defined disorder—Epirubicin—hematologic cancer	4.04e-06	3.65e-05	CcSEcCtD
Everolimus—Convulsion—Methotrexate—hematologic cancer	4.03e-06	3.64e-05	CcSEcCtD
Everolimus—Vomiting—Etoposide—hematologic cancer	4.03e-06	3.64e-05	CcSEcCtD
Everolimus—Erythema—Doxorubicin—hematologic cancer	4.03e-06	3.64e-05	CcSEcCtD
Everolimus—Malnutrition—Doxorubicin—hematologic cancer	4.03e-06	3.64e-05	CcSEcCtD
Everolimus—Anaemia—Epirubicin—hematologic cancer	4.02e-06	3.63e-05	CcSEcCtD
Everolimus—Agitation—Epirubicin—hematologic cancer	4e-06	3.61e-05	CcSEcCtD
Everolimus—Dyspepsia—Prednisone—hematologic cancer	4e-06	3.61e-05	CcSEcCtD
Everolimus—Rash—Etoposide—hematologic cancer	4e-06	3.61e-05	CcSEcCtD
Everolimus—Dermatitis—Etoposide—hematologic cancer	3.99e-06	3.61e-05	CcSEcCtD
Everolimus—Headache—Etoposide—hematologic cancer	3.97e-06	3.59e-05	CcSEcCtD
Everolimus—Flatulence—Doxorubicin—hematologic cancer	3.97e-06	3.58e-05	CcSEcCtD
Everolimus—Chest pain—Methotrexate—hematologic cancer	3.96e-06	3.58e-05	CcSEcCtD
Everolimus—Myalgia—Methotrexate—hematologic cancer	3.96e-06	3.58e-05	CcSEcCtD
Everolimus—Arthralgia—Methotrexate—hematologic cancer	3.96e-06	3.58e-05	CcSEcCtD
Everolimus—Decreased appetite—Prednisone—hematologic cancer	3.95e-06	3.57e-05	CcSEcCtD
Everolimus—Dysgeusia—Doxorubicin—hematologic cancer	3.94e-06	3.56e-05	CcSEcCtD
Everolimus—Rash—Prednisolone—hematologic cancer	3.94e-06	3.56e-05	CcSEcCtD
Everolimus—Dermatitis—Prednisolone—hematologic cancer	3.94e-06	3.56e-05	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	3.93e-06	3.55e-05	CcSEcCtD
Everolimus—Malaise—Epirubicin—hematologic cancer	3.92e-06	3.55e-05	CcSEcCtD
Everolimus—Fatigue—Prednisone—hematologic cancer	3.92e-06	3.54e-05	CcSEcCtD
Everolimus—Headache—Prednisolone—hematologic cancer	3.92e-06	3.54e-05	CcSEcCtD
Everolimus—Discomfort—Methotrexate—hematologic cancer	3.91e-06	3.53e-05	CcSEcCtD
Everolimus—Syncope—Epirubicin—hematologic cancer	3.9e-06	3.53e-05	CcSEcCtD
Everolimus—Leukopenia—Epirubicin—hematologic cancer	3.9e-06	3.52e-05	CcSEcCtD
Everolimus—Back pain—Doxorubicin—hematologic cancer	3.9e-06	3.52e-05	CcSEcCtD
Everolimus—Constipation—Prednisone—hematologic cancer	3.88e-06	3.51e-05	CcSEcCtD
Everolimus—Muscle spasms—Doxorubicin—hematologic cancer	3.87e-06	3.5e-05	CcSEcCtD
Everolimus—Palpitations—Epirubicin—hematologic cancer	3.85e-06	3.47e-05	CcSEcCtD
Everolimus—Loss of consciousness—Epirubicin—hematologic cancer	3.82e-06	3.46e-05	CcSEcCtD
Everolimus—Dizziness—Triamcinolone—hematologic cancer	3.8e-06	3.43e-05	CcSEcCtD
Everolimus—Cough—Epirubicin—hematologic cancer	3.8e-06	3.43e-05	CcSEcCtD
Everolimus—Vision blurred—Doxorubicin—hematologic cancer	3.79e-06	3.43e-05	CcSEcCtD
Everolimus—Convulsion—Epirubicin—hematologic cancer	3.77e-06	3.41e-05	CcSEcCtD
Everolimus—Infection—Methotrexate—hematologic cancer	3.77e-06	3.41e-05	CcSEcCtD
Everolimus—Nausea—Etoposide—hematologic cancer	3.76e-06	3.4e-05	CcSEcCtD
Everolimus—Hypertension—Epirubicin—hematologic cancer	3.76e-06	3.39e-05	CcSEcCtD
Everolimus—Feeling abnormal—Prednisone—hematologic cancer	3.74e-06	3.38e-05	CcSEcCtD
Everolimus—Asthenia—Dexamethasone—hematologic cancer	3.74e-06	3.38e-05	CcSEcCtD
Everolimus—Asthenia—Betamethasone—hematologic cancer	3.74e-06	3.38e-05	CcSEcCtD
Everolimus—Ill-defined disorder—Doxorubicin—hematologic cancer	3.74e-06	3.37e-05	CcSEcCtD
Everolimus—Nervous system disorder—Methotrexate—hematologic cancer	3.72e-06	3.36e-05	CcSEcCtD
Everolimus—Anaemia—Doxorubicin—hematologic cancer	3.72e-06	3.36e-05	CcSEcCtD
Everolimus—Thrombocytopenia—Methotrexate—hematologic cancer	3.72e-06	3.36e-05	CcSEcCtD
Everolimus—Gastrointestinal pain—Prednisone—hematologic cancer	3.71e-06	3.35e-05	CcSEcCtD
Everolimus—Nausea—Prednisolone—hematologic cancer	3.71e-06	3.35e-05	CcSEcCtD
Everolimus—Chest pain—Epirubicin—hematologic cancer	3.71e-06	3.35e-05	CcSEcCtD
Everolimus—Myalgia—Epirubicin—hematologic cancer	3.71e-06	3.35e-05	CcSEcCtD
Everolimus—Arthralgia—Epirubicin—hematologic cancer	3.71e-06	3.35e-05	CcSEcCtD
Everolimus—Agitation—Doxorubicin—hematologic cancer	3.7e-06	3.34e-05	CcSEcCtD
Everolimus—Anxiety—Epirubicin—hematologic cancer	3.69e-06	3.34e-05	CcSEcCtD
Everolimus—Pruritus—Dexamethasone—hematologic cancer	3.69e-06	3.33e-05	CcSEcCtD
Everolimus—Pruritus—Betamethasone—hematologic cancer	3.69e-06	3.33e-05	CcSEcCtD
Everolimus—Skin disorder—Methotrexate—hematologic cancer	3.69e-06	3.33e-05	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	3.68e-06	3.32e-05	CcSEcCtD
Everolimus—Hyperhidrosis—Methotrexate—hematologic cancer	3.67e-06	3.31e-05	CcSEcCtD
Everolimus—Discomfort—Epirubicin—hematologic cancer	3.66e-06	3.31e-05	CcSEcCtD
Everolimus—Vomiting—Triamcinolone—hematologic cancer	3.65e-06	3.3e-05	CcSEcCtD
Everolimus—Malaise—Doxorubicin—hematologic cancer	3.63e-06	3.28e-05	CcSEcCtD
Everolimus—Rash—Triamcinolone—hematologic cancer	3.62e-06	3.27e-05	CcSEcCtD
Everolimus—Dry mouth—Epirubicin—hematologic cancer	3.62e-06	3.27e-05	CcSEcCtD
Everolimus—Dermatitis—Triamcinolone—hematologic cancer	3.62e-06	3.27e-05	CcSEcCtD
Everolimus—Anorexia—Methotrexate—hematologic cancer	3.62e-06	3.27e-05	CcSEcCtD
Everolimus—Syncope—Doxorubicin—hematologic cancer	3.61e-06	3.26e-05	CcSEcCtD
Everolimus—Leukopenia—Doxorubicin—hematologic cancer	3.6e-06	3.26e-05	CcSEcCtD
Everolimus—Headache—Triamcinolone—hematologic cancer	3.6e-06	3.25e-05	CcSEcCtD
Everolimus—Abdominal pain—Prednisone—hematologic cancer	3.59e-06	3.24e-05	CcSEcCtD
Everolimus—Body temperature increased—Prednisone—hematologic cancer	3.59e-06	3.24e-05	CcSEcCtD
Everolimus—Diarrhoea—Dexamethasone—hematologic cancer	3.57e-06	3.22e-05	CcSEcCtD
Everolimus—Diarrhoea—Betamethasone—hematologic cancer	3.57e-06	3.22e-05	CcSEcCtD
Everolimus—Palpitations—Doxorubicin—hematologic cancer	3.56e-06	3.21e-05	CcSEcCtD
Everolimus—Oedema—Epirubicin—hematologic cancer	3.55e-06	3.21e-05	CcSEcCtD
Everolimus—Hypotension—Methotrexate—hematologic cancer	3.55e-06	3.2e-05	CcSEcCtD
Everolimus—Loss of consciousness—Doxorubicin—hematologic cancer	3.54e-06	3.2e-05	CcSEcCtD
Everolimus—Infection—Epirubicin—hematologic cancer	3.53e-06	3.19e-05	CcSEcCtD
Everolimus—Cough—Doxorubicin—hematologic cancer	3.51e-06	3.17e-05	CcSEcCtD
Everolimus—Shock—Epirubicin—hematologic cancer	3.49e-06	3.16e-05	CcSEcCtD
Everolimus—Convulsion—Doxorubicin—hematologic cancer	3.49e-06	3.15e-05	CcSEcCtD
Everolimus—Nervous system disorder—Epirubicin—hematologic cancer	3.48e-06	3.15e-05	CcSEcCtD
Everolimus—Thrombocytopenia—Epirubicin—hematologic cancer	3.48e-06	3.14e-05	CcSEcCtD
Everolimus—Hypertension—Doxorubicin—hematologic cancer	3.48e-06	3.14e-05	CcSEcCtD
Everolimus—Tachycardia—Epirubicin—hematologic cancer	3.47e-06	3.13e-05	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Methotrexate—hematologic cancer	3.46e-06	3.12e-05	CcSEcCtD
Everolimus—Skin disorder—Epirubicin—hematologic cancer	3.45e-06	3.12e-05	CcSEcCtD
Everolimus—Dizziness—Betamethasone—hematologic cancer	3.45e-06	3.11e-05	CcSEcCtD
Everolimus—Dizziness—Dexamethasone—hematologic cancer	3.45e-06	3.11e-05	CcSEcCtD
Everolimus—Hyperhidrosis—Epirubicin—hematologic cancer	3.43e-06	3.1e-05	CcSEcCtD
Everolimus—Insomnia—Methotrexate—hematologic cancer	3.43e-06	3.1e-05	CcSEcCtD
Everolimus—Arthralgia—Doxorubicin—hematologic cancer	3.43e-06	3.1e-05	CcSEcCtD
Everolimus—Chest pain—Doxorubicin—hematologic cancer	3.43e-06	3.1e-05	CcSEcCtD
Everolimus—Myalgia—Doxorubicin—hematologic cancer	3.43e-06	3.1e-05	CcSEcCtD
Everolimus—Anxiety—Doxorubicin—hematologic cancer	3.42e-06	3.09e-05	CcSEcCtD
Everolimus—Nausea—Triamcinolone—hematologic cancer	3.41e-06	3.08e-05	CcSEcCtD
Everolimus—Paraesthesia—Methotrexate—hematologic cancer	3.41e-06	3.08e-05	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	3.4e-06	3.08e-05	CcSEcCtD
Everolimus—Discomfort—Doxorubicin—hematologic cancer	3.39e-06	3.06e-05	CcSEcCtD
Everolimus—Anorexia—Epirubicin—hematologic cancer	3.39e-06	3.06e-05	CcSEcCtD
Everolimus—Dyspnoea—Methotrexate—hematologic cancer	3.38e-06	3.06e-05	CcSEcCtD
Everolimus—Somnolence—Methotrexate—hematologic cancer	3.37e-06	3.05e-05	CcSEcCtD
Everolimus—Dry mouth—Doxorubicin—hematologic cancer	3.35e-06	3.03e-05	CcSEcCtD
Everolimus—Hypersensitivity—Prednisone—hematologic cancer	3.35e-06	3.02e-05	CcSEcCtD
Everolimus—Dyspepsia—Methotrexate—hematologic cancer	3.34e-06	3.02e-05	CcSEcCtD
Everolimus—Hypotension—Epirubicin—hematologic cancer	3.32e-06	3e-05	CcSEcCtD
Everolimus—Vomiting—Betamethasone—hematologic cancer	3.32e-06	2.99e-05	CcSEcCtD
Everolimus—Vomiting—Dexamethasone—hematologic cancer	3.32e-06	2.99e-05	CcSEcCtD
Everolimus—Decreased appetite—Methotrexate—hematologic cancer	3.3e-06	2.98e-05	CcSEcCtD
Everolimus—Rash—Dexamethasone—hematologic cancer	3.29e-06	2.97e-05	CcSEcCtD
Everolimus—Rash—Betamethasone—hematologic cancer	3.29e-06	2.97e-05	CcSEcCtD
Everolimus—Oedema—Doxorubicin—hematologic cancer	3.29e-06	2.97e-05	CcSEcCtD
Everolimus—Dermatitis—Betamethasone—hematologic cancer	3.28e-06	2.97e-05	CcSEcCtD
Everolimus—Dermatitis—Dexamethasone—hematologic cancer	3.28e-06	2.97e-05	CcSEcCtD
Everolimus—Gastrointestinal disorder—Methotrexate—hematologic cancer	3.28e-06	2.96e-05	CcSEcCtD
Everolimus—Fatigue—Methotrexate—hematologic cancer	3.27e-06	2.96e-05	CcSEcCtD
Everolimus—Headache—Betamethasone—hematologic cancer	3.27e-06	2.95e-05	CcSEcCtD
Everolimus—Headache—Dexamethasone—hematologic cancer	3.27e-06	2.95e-05	CcSEcCtD
Everolimus—Infection—Doxorubicin—hematologic cancer	3.26e-06	2.95e-05	CcSEcCtD
Everolimus—Asthenia—Prednisone—hematologic cancer	3.26e-06	2.94e-05	CcSEcCtD
Everolimus—Pain—Methotrexate—hematologic cancer	3.25e-06	2.93e-05	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Epirubicin—hematologic cancer	3.24e-06	2.92e-05	CcSEcCtD
Everolimus—Shock—Doxorubicin—hematologic cancer	3.23e-06	2.92e-05	CcSEcCtD
Everolimus—Nervous system disorder—Doxorubicin—hematologic cancer	3.22e-06	2.91e-05	CcSEcCtD
Everolimus—Thrombocytopenia—Doxorubicin—hematologic cancer	3.22e-06	2.91e-05	CcSEcCtD
Everolimus—Pruritus—Prednisone—hematologic cancer	3.21e-06	2.9e-05	CcSEcCtD
Everolimus—Insomnia—Epirubicin—hematologic cancer	3.21e-06	2.9e-05	CcSEcCtD
Everolimus—Tachycardia—Doxorubicin—hematologic cancer	3.21e-06	2.9e-05	CcSEcCtD
Everolimus—Skin disorder—Doxorubicin—hematologic cancer	3.19e-06	2.88e-05	CcSEcCtD
Everolimus—Paraesthesia—Epirubicin—hematologic cancer	3.19e-06	2.88e-05	CcSEcCtD
Everolimus—Hyperhidrosis—Doxorubicin—hematologic cancer	3.18e-06	2.87e-05	CcSEcCtD
Everolimus—Dyspnoea—Epirubicin—hematologic cancer	3.17e-06	2.86e-05	CcSEcCtD
Everolimus—Somnolence—Epirubicin—hematologic cancer	3.16e-06	2.85e-05	CcSEcCtD
Everolimus—Anorexia—Doxorubicin—hematologic cancer	3.13e-06	2.83e-05	CcSEcCtD
Everolimus—Feeling abnormal—Methotrexate—hematologic cancer	3.13e-06	2.83e-05	CcSEcCtD
Everolimus—Dyspepsia—Epirubicin—hematologic cancer	3.13e-06	2.82e-05	CcSEcCtD
Everolimus—Diarrhoea—Prednisone—hematologic cancer	3.11e-06	2.81e-05	CcSEcCtD
Everolimus—Gastrointestinal pain—Methotrexate—hematologic cancer	3.1e-06	2.8e-05	CcSEcCtD
Everolimus—Nausea—Dexamethasone—hematologic cancer	3.1e-06	2.8e-05	CcSEcCtD
Everolimus—Nausea—Betamethasone—hematologic cancer	3.1e-06	2.8e-05	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—CCL2—hematologic cancer	3.09e-06	5.01e-05	CbGpPWpGaD
Everolimus—Decreased appetite—Epirubicin—hematologic cancer	3.09e-06	2.79e-05	CcSEcCtD
Everolimus—MTOR—Disease—PDGFB—hematologic cancer	3.09e-06	5.01e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SYK—hematologic cancer	3.08e-06	5e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HSP90AA1—hematologic cancer	3.08e-06	5e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL6R—hematologic cancer	3.08e-06	5e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CREBBP—hematologic cancer	3.08e-06	4.99e-05	CbGpPWpGaD
Everolimus—Hypotension—Doxorubicin—hematologic cancer	3.07e-06	2.77e-05	CcSEcCtD
Everolimus—Gastrointestinal disorder—Epirubicin—hematologic cancer	3.07e-06	2.77e-05	CcSEcCtD
Everolimus—Fatigue—Epirubicin—hematologic cancer	3.06e-06	2.77e-05	CcSEcCtD
Everolimus—MTOR—Innate Immune System—SRC—hematologic cancer	3.04e-06	4.94e-05	CbGpPWpGaD
Everolimus—Pain—Epirubicin—hematologic cancer	3.04e-06	2.74e-05	CcSEcCtD
Everolimus—Constipation—Epirubicin—hematologic cancer	3.04e-06	2.74e-05	CcSEcCtD
Everolimus—MTOR—Disease—TSC2—hematologic cancer	3.02e-06	4.9e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—ICAM1—hematologic cancer	3e-06	4.87e-05	CbGpPWpGaD
Everolimus—Dizziness—Prednisone—hematologic cancer	3e-06	2.71e-05	CcSEcCtD
Everolimus—Abdominal pain—Methotrexate—hematologic cancer	3e-06	2.71e-05	CcSEcCtD
Everolimus—Body temperature increased—Methotrexate—hematologic cancer	3e-06	2.71e-05	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	2.99e-06	2.7e-05	CcSEcCtD
Everolimus—FKBP1A—Disease—EP300—hematologic cancer	2.99e-06	4.85e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—BAD—hematologic cancer	2.98e-06	4.83e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—NFKBIA—hematologic cancer	2.98e-06	4.83e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—STAT1—hematologic cancer	2.97e-06	4.82e-05	CbGpPWpGaD
Everolimus—Insomnia—Doxorubicin—hematologic cancer	2.97e-06	2.68e-05	CcSEcCtD
Everolimus—Paraesthesia—Doxorubicin—hematologic cancer	2.95e-06	2.67e-05	CcSEcCtD
Everolimus—CYP3A4—Metabolism—HDC—hematologic cancer	2.95e-06	4.78e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MAP2K1—hematologic cancer	2.94e-06	4.76e-05	CbGpPWpGaD
Everolimus—Dyspnoea—Doxorubicin—hematologic cancer	2.93e-06	2.65e-05	CcSEcCtD
Everolimus—MTOR—Innate Immune System—NRAS—hematologic cancer	2.93e-06	4.75e-05	CbGpPWpGaD
Everolimus—Feeling abnormal—Epirubicin—hematologic cancer	2.93e-06	2.64e-05	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—SRC—hematologic cancer	2.92e-06	4.74e-05	CbGpPWpGaD
Everolimus—Somnolence—Doxorubicin—hematologic cancer	2.92e-06	2.64e-05	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—PIK3CD—hematologic cancer	2.92e-06	4.73e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—SRC—hematologic cancer	2.91e-06	4.72e-05	CbGpPWpGaD
Everolimus—Gastrointestinal pain—Epirubicin—hematologic cancer	2.9e-06	2.62e-05	CcSEcCtD
Everolimus—MTOR—Disease—FGFR3—hematologic cancer	2.9e-06	4.71e-05	CbGpPWpGaD
Everolimus—Dyspepsia—Doxorubicin—hematologic cancer	2.89e-06	2.61e-05	CcSEcCtD
Everolimus—MTOR—Immune System—CD80—hematologic cancer	2.89e-06	4.69e-05	CbGpPWpGaD
Everolimus—Vomiting—Prednisone—hematologic cancer	2.89e-06	2.61e-05	CcSEcCtD
Everolimus—MTOR—Immune System—KIT—hematologic cancer	2.89e-06	4.68e-05	CbGpPWpGaD
Everolimus—Rash—Prednisone—hematologic cancer	2.86e-06	2.59e-05	CcSEcCtD
Everolimus—Dermatitis—Prednisone—hematologic cancer	2.86e-06	2.58e-05	CcSEcCtD
Everolimus—Decreased appetite—Doxorubicin—hematologic cancer	2.86e-06	2.58e-05	CcSEcCtD
Everolimus—Headache—Prednisone—hematologic cancer	2.84e-06	2.57e-05	CcSEcCtD
Everolimus—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.84e-06	2.56e-05	CcSEcCtD
Everolimus—MTOR—Immune System—PTPN11—hematologic cancer	2.84e-06	4.6e-05	CbGpPWpGaD
Everolimus—Fatigue—Doxorubicin—hematologic cancer	2.83e-06	2.56e-05	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—NRAS—hematologic cancer	2.81e-06	4.56e-05	CbGpPWpGaD
Everolimus—Pain—Doxorubicin—hematologic cancer	2.81e-06	2.54e-05	CcSEcCtD
Everolimus—Constipation—Doxorubicin—hematologic cancer	2.81e-06	2.54e-05	CcSEcCtD
Everolimus—Abdominal pain—Epirubicin—hematologic cancer	2.81e-06	2.54e-05	CcSEcCtD
Everolimus—Body temperature increased—Epirubicin—hematologic cancer	2.81e-06	2.54e-05	CcSEcCtD
Everolimus—FKBP1A—Disease—STAT3—hematologic cancer	2.81e-06	4.55e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—MAPK3—hematologic cancer	2.8e-06	4.55e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NRAS—hematologic cancer	2.8e-06	4.54e-05	CbGpPWpGaD
Everolimus—Hypersensitivity—Methotrexate—hematologic cancer	2.8e-06	2.53e-05	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—FGF2—hematologic cancer	2.79e-06	4.53e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GRB2—hematologic cancer	2.78e-06	4.51e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PDGFA—hematologic cancer	2.77e-06	4.5e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3R1—hematologic cancer	2.75e-06	4.47e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—FOS—hematologic cancer	2.75e-06	4.46e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—BAD—hematologic cancer	2.75e-06	4.46e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—CREB1—hematologic cancer	2.75e-06	4.46e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KITLG—hematologic cancer	2.73e-06	4.44e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—NOTCH1—hematologic cancer	2.73e-06	4.42e-05	CbGpPWpGaD
Everolimus—Asthenia—Methotrexate—hematologic cancer	2.72e-06	2.46e-05	CcSEcCtD
Everolimus—Feeling abnormal—Doxorubicin—hematologic cancer	2.71e-06	2.45e-05	CcSEcCtD
Everolimus—Nausea—Prednisone—hematologic cancer	2.7e-06	2.44e-05	CcSEcCtD
Everolimus—CYP3A4—Metabolism—CDA—hematologic cancer	2.69e-06	4.37e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—CASP8—hematologic cancer	2.69e-06	4.36e-05	CbGpPWpGaD
Everolimus—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.69e-06	2.43e-05	CcSEcCtD
Everolimus—Pruritus—Methotrexate—hematologic cancer	2.69e-06	2.43e-05	CcSEcCtD
Everolimus—FKBP1A—Disease—MAPK3—hematologic cancer	2.68e-06	4.35e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6R—hematologic cancer	2.68e-06	4.35e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—JAK2—hematologic cancer	2.68e-06	4.34e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—CREBBP—hematologic cancer	2.68e-06	4.34e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—STAT5A—hematologic cancer	2.67e-06	4.34e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—CD80—hematologic cancer	2.67e-06	4.33e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—KIT—hematologic cancer	2.67e-06	4.32e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CDKN2B—hematologic cancer	2.65e-06	4.3e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PTPN11—hematologic cancer	2.62e-06	4.25e-05	CbGpPWpGaD
Everolimus—Hypersensitivity—Epirubicin—hematologic cancer	2.62e-06	2.36e-05	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—MDM2—hematologic cancer	2.61e-06	4.24e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MYC—hematologic cancer	2.61e-06	4.23e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—TGFB1—hematologic cancer	2.6e-06	4.22e-05	CbGpPWpGaD
Everolimus—Abdominal pain—Doxorubicin—hematologic cancer	2.6e-06	2.35e-05	CcSEcCtD
Everolimus—Body temperature increased—Doxorubicin—hematologic cancer	2.6e-06	2.35e-05	CcSEcCtD
Everolimus—Diarrhoea—Methotrexate—hematologic cancer	2.6e-06	2.35e-05	CcSEcCtD
Everolimus—CYP3A4—Metabolism—PC—hematologic cancer	2.59e-06	4.21e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CD86—hematologic cancer	2.56e-06	4.16e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—MAP2K1—hematologic cancer	2.55e-06	4.14e-05	CbGpPWpGaD
Everolimus—Asthenia—Epirubicin—hematologic cancer	2.55e-06	2.3e-05	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—MTOR—hematologic cancer	2.54e-06	4.12e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CB—hematologic cancer	2.54e-06	4.12e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIK3CD—hematologic cancer	2.54e-06	4.12e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—CREB1—hematologic cancer	2.54e-06	4.12e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HES1—hematologic cancer	2.53e-06	4.1e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—KRAS—hematologic cancer	2.52e-06	4.09e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NCOR1—hematologic cancer	2.51e-06	4.08e-05	CbGpPWpGaD
Everolimus—Pruritus—Epirubicin—hematologic cancer	2.51e-06	2.27e-05	CcSEcCtD
Everolimus—Dizziness—Methotrexate—hematologic cancer	2.51e-06	2.27e-05	CcSEcCtD
Everolimus—MTOR—Disease—BRAF—hematologic cancer	2.51e-06	4.06e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GBA—hematologic cancer	2.5e-06	4.06e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLC35B2—hematologic cancer	2.5e-06	4.06e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FGF1—hematologic cancer	2.49e-06	4.03e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CSF2—hematologic cancer	2.49e-06	4.03e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—IL6R—hematologic cancer	2.47e-06	4.01e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—CREBBP—hematologic cancer	2.47e-06	4.01e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FOXO1—hematologic cancer	2.45e-06	3.97e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PDGFRB—hematologic cancer	2.44e-06	3.97e-05	CbGpPWpGaD
Everolimus—Diarrhoea—Epirubicin—hematologic cancer	2.43e-06	2.2e-05	CcSEcCtD
Everolimus—MTOR—Immune System—FGF2—hematologic cancer	2.43e-06	3.94e-05	CbGpPWpGaD
Everolimus—Hypersensitivity—Doxorubicin—hematologic cancer	2.42e-06	2.19e-05	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—KRAS—hematologic cancer	2.42e-06	3.93e-05	CbGpPWpGaD
Everolimus—Vomiting—Methotrexate—hematologic cancer	2.41e-06	2.18e-05	CcSEcCtD
Everolimus—FKBP1A—Disease—KRAS—hematologic cancer	2.41e-06	3.91e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PDGFRA—hematologic cancer	2.41e-06	3.9e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—JAK1—hematologic cancer	2.4e-06	3.89e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PRKCG—hematologic cancer	2.4e-06	3.89e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIK3R1—hematologic cancer	2.4e-06	3.89e-05	CbGpPWpGaD
Everolimus—Rash—Methotrexate—hematologic cancer	2.39e-06	2.16e-05	CcSEcCtD
Everolimus—Dermatitis—Methotrexate—hematologic cancer	2.39e-06	2.16e-05	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—CDKN1B—hematologic cancer	2.39e-06	3.87e-05	CbGpPWpGaD
Everolimus—Headache—Methotrexate—hematologic cancer	2.38e-06	2.15e-05	CcSEcCtD
Everolimus—MTOR—Disease—MAP2K1—hematologic cancer	2.36e-06	3.83e-05	CbGpPWpGaD
Everolimus—Asthenia—Doxorubicin—hematologic cancer	2.36e-06	2.13e-05	CcSEcCtD
Everolimus—Dizziness—Epirubicin—hematologic cancer	2.35e-06	2.12e-05	CcSEcCtD
Everolimus—MTOR—Disease—PIK3CD—hematologic cancer	2.34e-06	3.8e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CASP3—hematologic cancer	2.34e-06	3.79e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL2—hematologic cancer	2.34e-06	3.79e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—JAK2—hematologic cancer	2.33e-06	3.78e-05	CbGpPWpGaD
Everolimus—Pruritus—Doxorubicin—hematologic cancer	2.33e-06	2.1e-05	CcSEcCtD
Everolimus—MTOR—Innate Immune System—PIK3CA—hematologic cancer	2.31e-06	3.76e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—BCL2—hematologic cancer	2.31e-06	3.74e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—MTAP—hematologic cancer	2.29e-06	3.72e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—IFNG—hematologic cancer	2.29e-06	3.71e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCND1—hematologic cancer	2.28e-06	3.69e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—MDM2—hematologic cancer	2.27e-06	3.69e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—JUN—hematologic cancer	2.27e-06	3.68e-05	CbGpPWpGaD
Everolimus—Vomiting—Epirubicin—hematologic cancer	2.26e-06	2.04e-05	CcSEcCtD
Everolimus—Nausea—Methotrexate—hematologic cancer	2.25e-06	2.04e-05	CcSEcCtD
Everolimus—Diarrhoea—Doxorubicin—hematologic cancer	2.25e-06	2.03e-05	CcSEcCtD
Everolimus—MTOR—Disease—FGF2—hematologic cancer	2.24e-06	3.64e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL2RA—hematologic cancer	2.24e-06	3.63e-05	CbGpPWpGaD
Everolimus—Rash—Epirubicin—hematologic cancer	2.24e-06	2.02e-05	CcSEcCtD
Everolimus—Dermatitis—Epirubicin—hematologic cancer	2.24e-06	2.02e-05	CcSEcCtD
Everolimus—Headache—Epirubicin—hematologic cancer	2.23e-06	2.01e-05	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—PIK3CA—hematologic cancer	2.22e-06	3.61e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TERT—hematologic cancer	2.22e-06	3.59e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PIK3CA—hematologic cancer	2.21e-06	3.59e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PIK3R1—hematologic cancer	2.21e-06	3.59e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIK3CB—hematologic cancer	2.21e-06	3.59e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD4—hematologic cancer	2.21e-06	3.58e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CDKN1A—hematologic cancer	2.2e-06	3.57e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PTEN—hematologic cancer	2.2e-06	3.56e-05	CbGpPWpGaD
Everolimus—Dizziness—Doxorubicin—hematologic cancer	2.17e-06	1.96e-05	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—PDGFB—hematologic cancer	2.16e-06	3.51e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—JAK2—hematologic cancer	2.15e-06	3.49e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MAPK8—hematologic cancer	2.15e-06	3.49e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—HRAS—hematologic cancer	2.14e-06	3.47e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TSC2—hematologic cancer	2.11e-06	3.43e-05	CbGpPWpGaD
Everolimus—Nausea—Epirubicin—hematologic cancer	2.11e-06	1.91e-05	CcSEcCtD
Everolimus—MTOR—Disease—MDM2—hematologic cancer	2.1e-06	3.4e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EP300—hematologic cancer	2.1e-06	3.4e-05	CbGpPWpGaD
Everolimus—Vomiting—Doxorubicin—hematologic cancer	2.09e-06	1.89e-05	CcSEcCtD
Everolimus—MTOR—Immune System—CDKN1B—hematologic cancer	2.08e-06	3.37e-05	CbGpPWpGaD
Everolimus—Rash—Doxorubicin—hematologic cancer	2.07e-06	1.87e-05	CcSEcCtD
Everolimus—Dermatitis—Doxorubicin—hematologic cancer	2.07e-06	1.87e-05	CcSEcCtD
Everolimus—Headache—Doxorubicin—hematologic cancer	2.06e-06	1.86e-05	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—HRAS—hematologic cancer	2.06e-06	3.34e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IL6—hematologic cancer	2.05e-06	3.33e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—HRAS—hematologic cancer	2.05e-06	3.32e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PIK3CB—hematologic cancer	2.04e-06	3.31e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—FHL2—hematologic cancer	2.04e-06	3.31e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL1B—hematologic cancer	2.04e-06	3.31e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—CD4—hematologic cancer	2.04e-06	3.31e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SRC—hematologic cancer	2.04e-06	3.31e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FGFR3—hematologic cancer	2.03e-06	3.3e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL2—hematologic cancer	2.03e-06	3.3e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MAPK14—hematologic cancer	2.01e-06	3.26e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AGRN—hematologic cancer	2e-06	3.25e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—VEGFA—hematologic cancer	1.98e-06	3.22e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—JUN—hematologic cancer	1.98e-06	3.21e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ESR1—hematologic cancer	1.97e-06	3.2e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—STAT3—hematologic cancer	1.96e-06	3.19e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NRAS—hematologic cancer	1.96e-06	3.18e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IL6—hematologic cancer	1.96e-06	3.18e-05	CbGpPWpGaD
Everolimus—Nausea—Doxorubicin—hematologic cancer	1.95e-06	1.76e-05	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—FN1—hematologic cancer	1.95e-06	3.16e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—BAD—hematologic cancer	1.93e-06	3.13e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NFKBIA—hematologic cancer	1.93e-06	3.13e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—CDKN1B—hematologic cancer	1.92e-06	3.11e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—CDKN1A—hematologic cancer	1.92e-06	3.11e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—PTEN—hematologic cancer	1.91e-06	3.1e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NOTCH1—hematologic cancer	1.91e-06	3.1e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—IDH2—hematologic cancer	1.9e-06	3.08e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HMMR—hematologic cancer	1.9e-06	3.08e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—AKT1—hematologic cancer	1.89e-06	3.07e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MAPK3—hematologic cancer	1.88e-06	3.05e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—MAPK8—hematologic cancer	1.87e-06	3.03e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CD80—hematologic cancer	1.87e-06	3.03e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KIT—hematologic cancer	1.87e-06	3.03e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CG—hematologic cancer	1.87e-06	3.03e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PTPN11—hematologic cancer	1.83e-06	2.97e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MYC—hematologic cancer	1.83e-06	2.96e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—EP300—hematologic cancer	1.82e-06	2.96e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TGFB1—hematologic cancer	1.82e-06	2.95e-05	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—AKT1—hematologic cancer	1.82e-06	2.95e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—AKT1—hematologic cancer	1.81e-06	2.93e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ARNTL—hematologic cancer	1.78e-06	2.9e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CREB1—hematologic cancer	1.78e-06	2.88e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—SRC—hematologic cancer	1.77e-06	2.88e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—CDKN1A—hematologic cancer	1.77e-06	2.87e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PTEN—hematologic cancer	1.76e-06	2.86e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—BRAF—hematologic cancer	1.75e-06	2.85e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCL2—hematologic cancer	1.74e-06	2.82e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CA9—hematologic cancer	1.74e-06	2.82e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ACP5—hematologic cancer	1.74e-06	2.82e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6R—hematologic cancer	1.73e-06	2.81e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CREBBP—hematologic cancer	1.73e-06	2.81e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NCOR2—hematologic cancer	1.71e-06	2.78e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—STAT3—hematologic cancer	1.71e-06	2.77e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—NRAS—hematologic cancer	1.71e-06	2.77e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KRAS—hematologic cancer	1.69e-06	2.74e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—EP300—hematologic cancer	1.68e-06	2.73e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MAP2K1—hematologic cancer	1.65e-06	2.68e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CD—hematologic cancer	1.64e-06	2.66e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—SRC—hematologic cancer	1.64e-06	2.65e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—MAPK3—hematologic cancer	1.63e-06	2.65e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—IDH1—hematologic cancer	1.63e-06	2.65e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—TXN—hematologic cancer	1.61e-06	2.62e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTO1—hematologic cancer	1.61e-06	2.62e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ABCC3—hematologic cancer	1.61e-06	2.62e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SPHK1—hematologic cancer	1.58e-06	2.56e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—STAT3—hematologic cancer	1.58e-06	2.56e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—NRAS—hematologic cancer	1.57e-06	2.55e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FGF2—hematologic cancer	1.57e-06	2.55e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CA—hematologic cancer	1.55e-06	2.51e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3R1—hematologic cancer	1.55e-06	2.51e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—UGT1A1—hematologic cancer	1.52e-06	2.46e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—MAPK3—hematologic cancer	1.51e-06	2.45e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—JAK2—hematologic cancer	1.51e-06	2.44e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TP53—hematologic cancer	1.5e-06	2.43e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLC22A1—hematologic cancer	1.48e-06	2.39e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CRABP1—hematologic cancer	1.48e-06	2.39e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MDM2—hematologic cancer	1.47e-06	2.38e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—KRAS—hematologic cancer	1.47e-06	2.38e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—MYC—hematologic cancer	1.47e-06	2.38e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—TGFB1—hematologic cancer	1.46e-06	2.37e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALOX5—hematologic cancer	1.44e-06	2.33e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HRAS—hematologic cancer	1.43e-06	2.33e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CB—hematologic cancer	1.43e-06	2.32e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NUP98—hematologic cancer	1.39e-06	2.26e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL6—hematologic cancer	1.37e-06	2.23e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—KRAS—hematologic cancer	1.35e-06	2.2e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ADCY7—hematologic cancer	1.35e-06	2.19e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NCOA3—hematologic cancer	1.35e-06	2.19e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIK3CA—hematologic cancer	1.35e-06	2.19e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NUP214—hematologic cancer	1.34e-06	2.18e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CDKN1B—hematologic cancer	1.34e-06	2.18e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ABCG2—hematologic cancer	1.32e-06	2.13e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—MTR—hematologic cancer	1.32e-06	2.13e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CASP3—hematologic cancer	1.32e-06	2.13e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL2—hematologic cancer	1.31e-06	2.13e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ENO2—hematologic cancer	1.29e-06	2.09e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCND1—hematologic cancer	1.28e-06	2.08e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—JUN—hematologic cancer	1.28e-06	2.07e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AKT1—hematologic cancer	1.27e-06	2.05e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTT1—hematologic cancer	1.25e-06	2.03e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—HRAS—hematologic cancer	1.25e-06	2.02e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PIK3CA—hematologic cancer	1.24e-06	2.02e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CDKN1A—hematologic cancer	1.24e-06	2.01e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PTEN—hematologic cancer	1.24e-06	2e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SDC1—hematologic cancer	1.22e-06	1.98e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MAPK8—hematologic cancer	1.21e-06	1.96e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6—hematologic cancer	1.19e-06	1.94e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EP300—hematologic cancer	1.18e-06	1.91e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—HRAS—hematologic cancer	1.15e-06	1.87e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SRC—hematologic cancer	1.15e-06	1.86e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—VEGFA—hematologic cancer	1.12e-06	1.81e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—STAT3—hematologic cancer	1.11e-06	1.79e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NRAS—hematologic cancer	1.1e-06	1.79e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—IL6—hematologic cancer	1.1e-06	1.79e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—AKT1—hematologic cancer	1.1e-06	1.79e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MAPK3—hematologic cancer	1.06e-06	1.71e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NQO1—hematologic cancer	1.04e-06	1.69e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CD44—hematologic cancer	1.04e-06	1.69e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MYC—hematologic cancer	1.03e-06	1.67e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TGFB1—hematologic cancer	1.02e-06	1.66e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—AKT1—hematologic cancer	1.02e-06	1.65e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYCS—hematologic cancer	9.84e-07	1.6e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	9.78e-07	1.59e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KRAS—hematologic cancer	9.49e-07	1.54e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CA—hematologic cancer	8.72e-07	1.41e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTP1—hematologic cancer	8.68e-07	1.41e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TP53—hematologic cancer	8.43e-07	1.37e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ABCB1—hematologic cancer	8.21e-07	1.33e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HRAS—hematologic cancer	8.07e-07	1.31e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NCOR1—hematologic cancer	7.97e-07	1.29e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTM1—hematologic cancer	7.97e-07	1.29e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6—hematologic cancer	7.72e-07	1.25e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AKT1—hematologic cancer	7.12e-07	1.16e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—MTHFR—hematologic cancer	7.05e-07	1.14e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CG—hematologic cancer	5.92e-07	9.6e-06	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CREBBP—hematologic cancer	5.49e-07	8.9e-06	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CD—hematologic cancer	5.2e-07	8.44e-06	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALB—hematologic cancer	5.14e-07	8.33e-06	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3R1—hematologic cancer	4.91e-07	7.97e-06	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CB—hematologic cancer	4.54e-07	7.36e-06	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTEN—hematologic cancer	3.92e-07	6.36e-06	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—EP300—hematologic cancer	3.74e-07	6.06e-06	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CA—hematologic cancer	2.77e-07	4.49e-06	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AKT1—hematologic cancer	2.26e-07	3.66e-06	CbGpPWpGaD
